Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
October 05, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James...
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
October 03, 2022 16:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split...
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
January 27, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity...
Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector
October 14, 2021 16:12 ET
|
Onxeo S.A.
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company’s Board as independent...
Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants
July 29, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs...
Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer
July 01, 2021 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company,...
Cocrystal Joins Russell Microcap® Index
June 28, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
June 23, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
June 09, 2021 14:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Closing of $40 Million Bought Deal
May 07, 2021 16:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...